Apitegromab

Apitegromab is an investigational study drug developed for diseases of muscle atrophy (a condition in which muscles are smaller and weaker than those of their peers), such as SMA. Apitegromab is designed to target muscle atrophy, muscle strength, and motor function.

“Investigational” means that apitegromab is still being studied in clinical research studies. It has been reviewed by a US Institutional Review Board (IRB) or a European Ethics Committee (EC) for testing in people. Apitegromab has not been approved by any health authorities, such as the US Food and Drug Administration (FDA), the European Medicine Agency (EMA), or the Medicines and Healthcare products Regulatory Agency (MHRA).